TLN 232

Drug Profile

TLN 232

Alternative Names: CAP-232; TLN-232; TT-232

Latest Information Update: 19 Aug 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biostatin Research and Development Ltd
  • Developer BELLUS Health
  • Class Antineoplastics; Cyclic peptides
  • Mechanism of Action Pyruvate kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Malignant melanoma; Pancreatic cancer; Renal cancer

Most Recent Events

  • 15 Aug 2013 Thallion Pharmaceuticals has been acquired and merged into BELLUS Health
  • 23 Jun 2010 Thallion Pharmaceuticals discontinues its development programme for TLN 232
  • 17 Jun 2010 Discontinued - Phase-II for Malignant melanoma in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top